Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare buprenorphine patch for induction (starting) of
buprenorphine in pregnant patients with opioid use disorder. The main questions it aims to
answer are:
1. Is there a buprenorphine induction method that results in the least moderate-to-severe
opioid withdrawal symptoms in pregnant patients with opioid use disorder?
2. Is there a buprenorphine induction method that results in a higher treatment success
rate? Under normal circumstances, patients who are planning to start sublingual (under
the tongue) buprenorphine for opioid use disorder must first go into withdrawal to start
the medication safely. Study participants will be given a buprenorphine patch during the
required withdrawal period before starting sublingual treatment, and be surveyed daily
by phone to assess their withdrawal symptoms. They will also be followed at prenatal
appointments to evaluate treatment success based on urine drug screen results.
Researchers will compare patients receiving no buprenorphine patch according to the
current standard care protocol.